CXR Biosciences Ltd. Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware
SEATTLE & DUNDEE, Scotland–(BUSINESS WIRE)–Rosetta Biosoftware announced today that CXR Biosciences Ltd. licensed the Rosetta Resolver® system to investigate mechanisms of drug toxicity. CXR Biosciences plans to use the statistical analysis tools in the Resolver system to generate high-quality data to support its toxicological research using transcriptional profiling.
“We appreciate Rosetta Biosoftware’s strong reputation for developing high-quality data management and statistical software for microarray analysis,” said Tom Shepherd, Ph.D., Chief Executive Officer of CXR Biosciences. “The Resolver system will provide us with a solid platform for determining the toxicological profiles of early-stage compounds, helping us to achieve one of CXR’s strategic aims, which is to revolutionize the human risk assessment of drugs and chemicals.”
“At Rosetta Biosoftware, we developed the Resolver system to be a flexible and scalable framework to grow with a researcher’s throughput needs,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. “We take pride in developing a robust data management and statistical analysis platform to support our customers. We are pleased to provide the Resolver system to CXR Biosciences to enable toxicology research in a preclinical drug development setting, and to enable CXR to produce reliable results from its data.”
About CXR Biosciences Ltd.
CXR Biosciences Ltd. is a Dundee, Scotland, based company focused on applying advanced molecular and genetic techniques to improve the development of new drugs. This is achieved by developing innovative approaches to improve the predictability and relevance to man of preclinical models. The company is built on the extensive experience in drug development and risk assessment of its founders, Professor Roland Wolf, and Dr. Cliff Elcombe, of Dundee University. To learn more about CXR Biosciences, visit www.cxrbiosciences.com.
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.
Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.
